Blueprint
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of March 2017
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
6 March 2017 07:00 GMT
CHANGES TO ASTRAZENECA BOARD OF DIRECTORS
AstraZeneca
today announced that Philip Broadley will be proposed to
shareholders for election as a Non-Executive Director of
AstraZeneca PLC at the Company's Annual General Meeting (AGM) on 27
April 2017. On election, the Board proposes appointing Mr Broadley
as a member of the Audit Committee.
Ann
Cairns, a Non-Executive Director, will step down from the
AstraZeneca Board and as a member of the Audit Committee with
effect from the end of the AGM on 27 April 2017.
Leif
Johansson, Chairman of AstraZeneca, said: "On behalf of the Board,
I'd like to thank Ann for her contribution to AstraZeneca, both as
a Board member and as a member of the Audit Committee over the last
three years. We wish her all the best for the future. I'm delighted
that the Board is proposing Philip Broadley for election as a
Non-Executive Director. His significant international business and
financial experience will prove a valuable addition to the Board
and we look forward to welcoming him."
Subject
to his election by shareholders, Mr Broadley will join the Board
and the Audit Committee with effect from the end of the AGM on 27
April 2017. The Notice of AGM is due to be published on or around
16 March 2017.
In
relation to Mr Broadley's proposed election, no disclosure
obligations arise under paragraphs (2) to (6) of LR 9.6.13 R of the
UK Listing Authority's Listing Rules. Details of directorships to
be disclosed under paragraph (1) of LR 9.6.13 R are included within
the biographical details below.
Philip Broadley - biographical details
Philip
has significant financial and international business experience,
having previously been Group Finance Director of Prudential plc for
eight years until 2008 and of Old Mutual plc for six years until
2014. He started his career at Arthur Andersen where he was a
partner for seven years. He is a past Chairman of the 100 Group of
Finance Directors in the UK. He is a Fellow of the Institute of
Chartered Accountants in England and Wales. He graduated in
Philosophy, Politics and Economics from St Edmund Hall, Oxford and
has an MSc in Behavioural Science from the London School of
Economics.
Philip
is a Non-Executive Director of Legal & General Group plc and
chairs its Audit Committee. He is a member of the Code Committee of
the UK Takeover Panel. He is a member of the Oxford University
Audit Committee, Treasurer of the London Library and a governor of
Eastbourne College.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that
focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of diseases in
three main therapy areas - Oncology, Cardiovascular &
Metabolic Diseases and
Respiratory. The Company also is selectively active in the areas of
Autoimmunity, Neuroscience and Infection. AstraZeneca operates in
over 100 countries and its innovative medicines are used by
millions of patients worldwide. For more information, please
visit www.astrazeneca.com and
follow us on Twitter @AstraZeneca.
|
Media
Enquiries
|
|
|
|
Esra
Erkal-Paler
|
UK/Global
|
+44 203
749 5638
|
|
Vanessa
Rhodes
|
UK/Global
|
+44 203
749 5736
|
|
Karen
Birmingham
|
UK/Global
|
+44 203
749 5634
|
|
Rob
Skelding
|
UK/Global
|
+44 203
749 5821
|
|
Jacob
Lund
|
Sweden
|
+46
8 553 260 20
|
|
Michele
Meixell
|
US
|
+1 302
885 2677
|
|
Investor
Relations
|
|
|
|
Thomas
Kudsk Larsen
|
|
+44 203
749 5712
|
|
Craig
Marks
|
Finance,
Fixed Income, M&A
|
+44
7881 615 764
|
|
Henry
Wheeler
|
Oncology
|
+44 203
749 5797
|
|
Mitchell
Chan
|
Oncology
|
+1 240
477 3771
|
|
Lindsey
Trickett
|
Cardiovascular
& Metabolic Diseases
|
+1 240
543 7970
|
|
Nick
Stone
|
Respiratory
|
+44 203
749 5716
|
|
Christer
Gruvris
|
Autoimmunity,
Neuroscience & Infection
|
+44 203
749 5711
|
|
US toll
free
|
|
+1 866
381 7277
|
Adrian Kemp
Company Secretary, AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
06 March 2017
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|